| Company | Value | Change | %Change |
|---|
The company’s earnings failed to meet analysts’ expectations on some fronts, reflecting ongoing cost pressures and pricing challenges.
Net profit came in at ₹845.8 crore, marking a 9.7% decline from ₹936 crore reported in the same quarter last year. This was also lower than the CNBC-TV18 poll estimate of ₹906 crore, indicating weaker-than-expected bottom-line performance.
Revenue, on the other hand, rose 8.5% year-on-year (YoY) to ₹7,978.5 crore, surpassing the CNBC-TV18 poll projection of ₹7,782.5 crore. The strong sales growth was supported by steady demand across key geographies, including the US and emerging markets.Also read: Emcure Pharma Q3 Results: Net profit jumps 30% on-year, margin shrinks
Operating performance remained subdued, with EBITDA falling 1.5% YoY to ₹1,627.7 crore, compared to ₹1,601 crore in the year-ago period. The number also came in below the CNBC-TV18 poll forecast of ₹1,636 crore.
Margins also contracted, declining to 20.4% from 21.8% last year, missing the poll estimate of 21%.
Ahead of earnings announcement, shares of Aurobindo Pharma ended the trading session flat at ₹1,184.50 apiece on the BSE, down 0.62%.
First Published: Feb 6, 2025 8:08 PM IS
